Nephrologist survey: Many chronic kidney disease patients might be good ... NephrologyNews.com Mircera is an erythropoietin receptor activator indicated for the treatment of symptomatic anemia in chronic kidney disease, which received FDA approval in November 2007. After reviewing a brief product profile, 49% of physicians are highly interested ... |
